

OPEN ACCESS



African Journal of
Microbiology Research

7 March 2019
ISSN 1996-0808
DOI: 10.5897/AJMR
www.academicjournals.org



**ACADEMIC
JOURNALS**
expand your knowledge

About AJMR

The African Journal of Microbiology Research (AJMR) is a peer reviewed journal. The journal is published weekly and covers all areas of subject as Environmental Microbiology, Clinical Microbiology, Immunology, Virology, Bacteriology, Phycology, Molecular and Cellular Biology, Molecular Microbiology, Food Microbiology, Mycology and Parasitology, Microbial Ecology, Probiotics and Prebiotics and Industrial Microbiology.

Indexing

[CAB Abstracts](#), [CABI's Global Health Database](#), [Chemical Abstracts \(CAS Source Index\)](#), [Dimensions Database](#), [Google Scholar](#), [Matrix of Information for The Analysis of Journals \(MIAR\)](#), [Microsoft Academic](#), [Research Gate](#)

Open Access Policy

Open Access is a publication model that enables the dissemination of research articles to the global community without restriction through the internet. All articles published under open access can be accessed by anyone with internet connection.

The African Journal of Microbiology Research is an Open Access journal. Abstracts and full texts of all articles published in this journal are freely accessible to everyone immediately after publication without any form of restriction.

Article License

All articles published by African Journal of Microbiology Research are licensed under the [Creative Commons Attribution 4.0 International License](#). This permits anyone to copy, redistribute, remix, transmit and adapt the work provided the original work and source is appropriately cited. Citation should include the article DOI. The article license is displayed on the abstract page the following statement:

This article is published under the terms of the [Creative Commons Attribution License 4.0](#). Please refer to <https://creativecommons.org/licenses/by/4.0/legalcode> for details about [Creative Commons Attribution License 4.0](#).

Article Copyright

When an article is published by in the African Journal of Microbiology Research, the author(s) of the article retain the copyright of article. Author(s) may republish the article as part of a book or other materials. When reusing a published article, author(s) should; Cite the original source of the publication when reusing the article. i.e. cite that the article was originally published in the African Journal of Microbiology Research. Include the article DOI
Accept that the article remains published by the African Journal of Microbiology Research (except in occasion of a retraction of the article)

The article is licensed under the Creative Commons Attribution 4.0 International License.

A copyright statement is stated in the abstract page of each article. The following statement is an example of a copyright statement on an abstract page.

Copyright ©2016 Author(s) retains the copyright of this article.

Self-Archiving Policy

The African Journal of Microbiology Research is a RoMEO green journal. This permits authors to archive any version of their article they find most suitable, including the published version on their institutional repository and any other suitable website.

Please see <http://www.sherpa.ac.uk/romeo/search.php?issn=1684-5315>

Digital Archiving Policy

The African Journal of Microbiology Research is committed to the long-term preservation of its content. All articles published by the journal are preserved by [Portico](#). In addition, the journal encourages authors to archive the published version of their articles on their institutional repositories and as well as other appropriate websites.

<https://www.portico.org/publishers/ajournals/>

Metadata Harvesting

The African Journal of Microbiology Research encourages metadata harvesting of all its content. The journal fully supports and implement the OAI version 2.0, which comes in a standard XML format. [See Harvesting Parameter](#)

Memberships and Standards



Academic Journals strongly supports the Open Access initiative. Abstracts and full texts of all articles published by Academic Journals are freely accessible to everyone immediately after publication.



All articles published by Academic Journals are licensed under the [Creative Commons Attribution 4.0 International License \(CC BY 4.0\)](#). This permits anyone to copy, redistribute, remix, transmit and adapt the work provided the original work and source is appropriately cited.



[Crossref](#) is an association of scholarly publishers that developed Digital Object Identification (DOI) system for the unique identification published materials. Academic Journals is a member of Crossref and uses the DOI system. All articles published by Academic Journals are issued DOI.

[Similarity Check](#) powered by iThenticate is an initiative started by CrossRef to help its members actively engage in efforts to prevent scholarly and professional plagiarism. Academic Journals is a member of Similarity Check.

[CrossRef Cited-by](#) Linking (formerly Forward Linking) is a service that allows you to discover how your publications are being cited and to incorporate that information into your online publication platform. Academic Journals is a member of [CrossRef Cited-by](#).



Academic Journals is a member of the [International Digital Publishing Forum \(IDPF\)](#). The IDPF is the global trade and standards organization dedicated to the development and promotion of electronic publishing and content consumption.

Contact

Editorial Office: ajmr@academicjournals.org

Help Desk: helpdesk@academicjournals.org

Website: <http://www.academicjournals.org/journal/AJMR>

Submit manuscript online <http://ms.academicjournals.org>

Academic Journals
73023 Victoria Island, Lagos, Nigeria
ICEA Building, 17th Floor,
Kenyatta Avenue, Nairobi, Kenya.

Editors

Prof. Adriano Gomes da Cruz
University of Campinas (UNICAMP),
Brazil.

Prof. Ashok Kumar
School of Biotechnology
Banaras Hindu University Uttar Pradesh,
India.

Dr. Mohd Fuat Abd Razak
Infectious Disease Research Centre,
Institute for Medical Research, Jalan
Pahang, Malaysia.

Dr. Adibe Maxwell Ogochukwu
Department of Clinical Pharmacy and
Pharmacy Management,
University of Nigeria
Nsukka, Nigeria.

Dr. Mehdi Azami
Parasitology & Mycology Department
Baghaeei Lab.
Isfahan, Iran.

Dr. Franco Mutinelli
Istituto Zooprofilattico Sperimentale delle
Venezie Italy.

Prof. Ebiamadon Andi Brisibe
University of Calabar,
Calabar,
Nigeria.

Prof. Nazime Mercan Dogan
Department of Biology
Faculty of Science and Arts
University Denizli Turkey.

Prof. Long-Liu Lin
Department of Applied Chemistry
National Chiayi University
Chiayi County Taiwan.

Prof. Natasha Potgieter
University of Venda
South Africa.

Dr. Tamer Edirne
Department of Family Medicine
University of Pamukkale
Turkey.

Dr. Kwabena Ofori-Kwakye
Department of Pharmaceutics
Kwame Nkrumah University of Science &
Technology
Kumasi, Ghana.

Dr. Tülin Askun
Department of Biology
Faculty of Sciences & Arts
Balikesir University Turkey.

Dr. Mahmoud A. M. Mohammed
Department of Food Hygiene and Control
Faculty of Veterinary Medicine
Mansoura University Egypt.

Editors

Dr. James Stefan Rokem

Department of Microbiology & Molecular Genetics
Institute of Medical Research Israel – Canada
The Hebrew University – Hadassah Medical School Jerusalem, Israel.

Dr. Afework Kassu

University of Gondar
Ethiopia.

Dr. Wael Elnaggar

Faculty of Pharmacy
Northern Border University
Rafha Saudi Arabia.

Dr. Maulin Shah

Industrial Waste Water Research Laboratory
Division of Applied & Environmental Microbiology, Enviro Technology Limited
Gujarat, India.

Dr. Ahmed Mohammed

Pathological Analysis Department
Thi-Qar University College of Science
Iraq.

Prof. Naziha Hassanein

Department of Microbiology
Faculty of Science
Ain Shams University
Egypt.

Dr. Shikha Thakur

Department of Microbiology
Sai Institute of Paramedical and Allied Sciences India.

Dr. Samuel K Ameyaw

Civista Medical Center
USA.

Dr. Anubrata Ghosal

Department of Biology
MIT - Massachusetts Institute of Technology
USA.

Dr. Bellamkonda Ramesh

Department of Food Technology
Vikrama Simhapuri University
India.

Dr. Sabiha Yusuf Essack

Department of Pharmaceutical Sciences
University of KwaZulu-Natal
South Africa.

Dr. Navneet Rai

Genome Center
University of California Davis USA.

Dr. Iheanyi Omezuruike Okonko

Department of Virology
Faculty of Basic Medical Sciences
University of Ibadan
Ibadan, Nigeria.

Dr. Mike Agenbag

Municipal Health Services,
Joe Gqabi,
South Africa.

Dr. Abdel-Hady El-Gilany

Department of Public Health & Community Medicine, Faculty of Medicine
Mansoura University
Egypt.

Table of Content

Inhibition of *Streptococcus mutans* (ATCC 25175) biofilm formation on eugenol-impregnated surgical sutures

Victor Alves Carneiro, Elaine de Fátima Furtado, Rafaela Mesquita Bastos Cavalcante, Maria Láina Silva, Rondinely Lima Silva, Queli Cristina Fidelis and Francisco Eduardo Aragão Catunda Júnior

Utility of molecular diagnostic method compared with conventional methods in detection of etiologic agents of central nervous system infections in Rwanda

Edouard Ntagwabira, Marianne Wanjiru Mureithi, Jean Baptiste Mazarati, Walter Jaoko and Omu Anzala

Full Length Research Paper

Inhibition of *Streptococcus mutans* (ATCC 25175) biofilm formation on eugenol-impregnated surgical sutures

Victor Alves Carneiro^{1,2*}, Elaine de Fátima Furtado¹, Rafaela Mesquita Bastos Cavalcante¹, Maria Laína Silva¹, Rondinely Lima Silva¹, Queli Cristina Fidelis³ and Francisco Eduardo Aragão Catunda Júnior⁴

¹Laboratory of Biofilms and Antimicrobial Agents (LaBAM), Faculty of Medicine, Federal University of Ceara – UFC, Sobral - Ceara, Brazil.

²Laboratory of Bioprospecting and Applied Molecular Experimentation (NUBEM), University Center INTA – UNINTA, Sobral - Ceara, Brazil

³Department of Science and Technology Federal University of Maranhao – UFMA, Balsas - Maranhao, Brazil.

⁴Exact, Natural and Technological Sciences Department – CCENT, State University of Tocantina Region of Maranhao – UEMASUL, Imperatriz - Maranhao, Brazil.

Received 19 December, 2018; Accepted 7 February, 2019

The use of bioactive compounds as anti-infective coating on biomaterial surfaces has been studied as a tool against microbial adhesion and the establishment of biofilms. The objective of this work was to evaluate the antibacterial activity of eugenol, specifically the ability to interact with cotton suture threads for preventing adhesion and biofilm formation of *Streptococcus mutans* (ATCC 25175). The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of eugenol were determined according to Clinical and Laboratory Standards Institute (CLSI), which showed respective concentration values of 250 and 1000 µg/ml. In addition, eugenol displayed marked activity against to biofilm formation in 96-well polystyrene plates against several strains from the *Streptococcus* genus, even at lower than bacteriostatic concentrations between 15 to 250 µg/ml. Moreover, eugenol formed an effective covering on cotton-suture surfaces that inhibited cell adhesion, which decreased the *S. mutans* (ATCC 25175) biofilm development, according to biomass and metabolic rate, quantified by crystal violet staining and XTT reduction, respectively. This research may help to explore the eugenol molecule as an antifouling coating on surfaces, bringing a new perspective to the prevention of infections associated with biomaterials.

Key words: Eugenol, biofilm formation, *Streptococcus mutans*, anti-infective surfaces.

INTRODUCTION

Biofilms are microbial communities physiologically distinct from their free-living counterparts, primarily because of the ability to produce an adhesive matrix rich in proteins and polymeric substances (Billings et al., 2015). The

presence of this matrix provides the biofilm with structural stability and offers a protection barrier against foreign agents, besides facilitating adhesion to biological and synthetic surfaces. These cellular clusters can establish

relationships of synergism and mutualism, generating cooperative benefits that favor the microbial community (Okuda et al., 2012).

Microbial colonization on the inserted or implanted foreign body material surface is known for biomaterials-associated infections (BAI) (Busscher et al., 2012). Suture threads used in surgical repairs represent a convenient target for attachment of cells and biofilm formation (Costa Neto et al., 2015). Microbial colonization on these surfaces may trigger severe tissue damage and compromise the success of the surgery (Chu et al., 1984).

Many types of bacteria have the ability to colonize the surfaces of the suture threads, triggering an infectious process in the tissues (Selvi et al., 2016). Once the biofilm has been established; as a consequence of the higher microbial resistance, the local decontamination mechanisms become ineffective, since these structured communities of microorganisms may harbor cells that are 10 to 1000 times more resistant to antimicrobial agents compared to their planktonic forms (Stewart, 2015). Due to high risk of infections, research in this area has focused primarily on how to avoid microbial adhesion and consequently biofilm formation in biomaterials (Chen et al., 2015; Meghil et al., 2015). One of the most promising approaches to combat microbial adhesion is through surface coating with bioactive substances (Bazaka et al., 2011; Trentin et al., 2015; Aranya et al., 2017).

Since 2002, Vicryl Plus was the first commercial antimicrobial suture approved by the US Food and Drug Administration (US FDA), and since then, this suture was clinically used as a useful alternative to decrease the risk factors for Surgical Site Infection (SSI), risk, even in oral surgery (Venema et al., 2011; Hoshino et al., 2013; Sewlikar et al., 2015). However, the efficacy of this suture is still unclear, and its clinical efficacy has been questioned in randomized controlled trials (Wu et al., 2017).

Conversely, antimicrobial molecules extracted from plants also present a promising strategy due to their relatively low toxicity, biocompatibility and low cost (Savoia, 2012; Al-Jumaili et al., 2018). Among these is eugenol (4-allyl-2-methoxyphenol), an aromatic substance found as the majority constituent in clove, cinnamon and myrrh (Khalil et al., 2017), which has been extensively employed in various dental procedures as an analgesic, local anesthetic, antiseptic, and even used in combination with zinc oxide to prepare dental cement (OZE).

Since the prevention or treatment of infections by coating surfaces with antimicrobial substances appears promising, the aim of this work was to evaluate the antibiofilm activity of eugenol against several commercial strains of the genus *Streptococcus* and to test it as an

anti-infective coating on cotton sutures by studying the effects on initial adhesion and biofilm development of *Streptococcus mutans* (ATCC 25175).

MATERIALS AND METHODS

Test compound - eugenol solution

Eugenol pure was commercially acquired from Sigma-Aldrich (ReagentPlus[®]), and used to prepare the stock solution at final concentration of 8000 µg/ml. First, eugenol was mixed onto 80 µl of DMSO (dimethyl sulfoxide), and then added fresh Brain Heart Infusion broth (BHI broth, Difco, Detroit, MI) up to 1 ml. Test solutions were made by serial-2-fold dilutions with concentrations ranging from 15 to 2000 µg/ml. To perform the antibiofilm assays on surgical sutures, a new eugenol solution was similarly prepared using PBS/DMSO buffer (sodium phosphate 100 mM with sodium chloride 150 mM, pH 12 and 8% DMSO), and diluted to different concentrations of 2000, 5000 and 8000 µg/ml. These concentrations were established to guarantee the eugenol covering on the suture samples. It was used as untreated group PBS/DMSO buffer, only. The amount of DMSO used to prepare the eugenol solution, as well as phosphate buffer has no effect on bacterial growth of the tested microbes.

Bacterial strains and culture conditions

Streptococcus mutans (ATCC 25175), *S. oralis* (ATCC 10517), *S. parasanguinis* (ATCC 503), *S. pyogenes* (ATCC 19615), *S. salivarius* (ATCC 7073) and *S. sp.* (ATCC 15300) were generously donated by Fundação Oswaldo Cruz (FIOCRUZ, Rio de Janeiro, Brazil). All bacteria were initially streaked from -80°C glycerol stocks onto BHI plates, and a fresh single colony was inoculated into BHI and cultured at 37°C under 5% of CO₂. Bacterial strains were collected by centrifugation (FS-15000CFN II, Vision Scientific, Daejeon, Korea) after 18 h growing at exponential phase, and the cell suspensions were adjusted against to 0.5 McFarland and recorded the optical densities at 620 nm by spectrophotometer (Biotrak II Reader - Amersham Biosciences, Cambridge, England), and then diluted until 10⁶ CFU/ml using fresh BHI.

Planktonic susceptibility testing

The antibacterial activity of eugenol was verified according to the microdilution test in 96-well polystyrene plates according to the Clinical and Laboratory Standards Institute (CLSI, 2012). Different eugenol concentrations were prepared as described above and added to the plates at a volume of 100 µl. The same volume of bacterial suspension was then added in each well to a final volume of 200 µl with a density of 5 x 10⁵ cells per well, and the plates were incubated for 24 h at 37°C under 5% of CO₂ (Shel Lab - TC2123-2E, Cornelius, USA). The MIC was defined as the lowest concentration that inhibits microbial growth detected by the unaided eye. To establish the MBC, 10 µl of broth from wells showing no visible microbial growth were plated onto BHI agar medium. After 24 h incubation under suitable conditions, the lowest concentration able to completely inhibit microbial growth was considered the

*Corresponding author. E-mail: viktorcarneiro@gmail.com. Tel: +55 85 999972060.

MBC. BHI broth without eugenol was used as controls. All MIC/MBC tests were performed in triplicate.

Antibiofilm activity *in vitro*

This assay investigated the ability of the compound to interfere in the initial steps of biofilm formation by using a 96-well, flat-bottom microtiter plate (Kasvi K12-096, Parana, Brazil). The prevention of biofilm formation (bacterial inoculation and drug exposure occur simultaneously) was defined as the lowest concentration of antimicrobial agent that resulted in an optical density (OD) 640 nm difference of the mean of positive control well readings, afterwards shown as percentage of biofilm biomass (Macià et al., 2014). Briefly, 100 µl of the serial dilutions of eugenol was added to each well, similar to planktonic susceptibility test, using BHI with 2% sucrose to perform all dilutions. About 100 µl of each bacterial suspension containing 10^6 cells/ml was then transferred into each well to allow biofilm formation for 24 h at 37°C, anaerobically. The extent of residual biofilm formation was measured using the crystal violet (CV) assay, as described by O'Toole (2011). Each strain was tested in triplicate at three independent assays.

Eugenol-impregnated (E) sutures procedure

Cotton-sutures (Techno 3-0/30 mm, São Paulo, Brazil) in a standard-cut size of 1 cm and sterilized in glass Petri dishes by autoclaving were placed individually into polystyrene 24-well plates. One milliliter of eugenol dissolved in PBS/DMSO buffer at concentrations of 2000, 5000 and 8000 µg/ml was added to the plates. PBS/DMSO buffer was used as a control to avoid any interference from DMSO and/or the pH buffer. This group was called the control (C) suture. Afterwards, the threads were incubated with orbital agitation (Marconi-MA 410, Piracicaba, SP, Brazil) overnight at 37°C, 100 rpm, and subsequently dried for approximately 1 - 2 h at room temperature before being used for subsequent assays.

Effect of E-suture on initial adhesion of bacteria

After drying, E-sutures were placed in contact by immersion into 1000 µl of microbial suspension containing 10^6 CFU/ml, and incubated for 6 h at 37°C with agitation of 100 rpm to allow the first step of initial adhesion of the biofilm formation process. During adherence analysis, sutures were washed twice using PBS buffer (sodium phosphate 100 mM, pH 7.0) and transferred to a new polystyrene 24-well plate with 1000 µl of same buffer to provide the detachment of the adhered cells through ultrasonic bath with 42 kHz and 0.17 kW. After 360 s of sonication, the bacterial suspension obtained was used to CFU count. Serial ten-fold dilution was prepared in fresh broth and plated onto BHI agar and incubated for 24 h at suitable conditions. The C-suture samples were used as a control group. The experiments were repeated at least three independent assays and were performed with six suture-samples per group.

Effect of E-suture on biofilm development

Sutures were incubated for 6 h to enable initial colonization, which was prepared as mentioned previously and afterward submitted to the biofilm formation tests by culturing for 48 h in 1000 µL of fresh BHI on 24-well polystyrene plate. Between intervals of 12 h, test (E) and control (C) sutures were analyzed for biomass production

(12/12 h), as well as cellular viability (24/24 h) by crystal violet quantification and the XTT assay (sodium-3-(1-((phenylamino)-carbonyl)-3,4-tetrazolium)-bis(4-methoxy-6-nitro)benzene-sulfonic acid hydrate), respectively. For biomass quantification by crystal violet staining, the suture threads under biofilm development were washed twice with PBS-buffer (pH 7.0) and then sequentially transferred to new wells with fresh broth culture. This procedure was repeated at 12, 24, 36 and 48 h after 6 h of initial adhesion. For each time, the E- and C-sutures samples were transferred to new 24-well plate and washed twice to remove loosely attached cells, before to biomass quantification through CV staining.

The XTT reduction assay was used to quantify the bacterial viability in cells firmly attached on the surface of E- and C-threads. Briefly, the solutions of XTT (1 mg/ml) (Sigma, St. Louis, MO, USA) and menadione (0.4 mM) (Fluka, Newport News, VA, USA) were prepared in PBS buffer and DMSO, respectively, before use. After 24 h of biofilm culturing, the suture samples were rinsed twice with PBS buffer to remove loosely attached cells, and allowed to air dry using a newly opened polystyrene 24-well plate. A PBS/XTT/Menadione solution (volume ratio of 79/20/1), was added (1000 µl) in every individual well containing pre-washed suture, and left for 5 h at 37°C in the dark. The reduction of XTT (oxidative activity) was then measured at 492 nm (Biotrak II Reader, Amersham Biosciences). This procedure was performed at the 24 and 48 h intervals after 6 h of initial adhesion. For the measurement of background XTT-colorimetric levels, suture threads exposed to the same solutions but only using sterile culture media was used. Each strain was tested in triplicate.

Statistical analysis

The results of the respective tests were categorized in Microsoft Excel (Version 2012 for Windows) and were analyzed in GraphPad Prism software (Version 5.0 for Windows, San Diego, California, USA). Significant differences between the groups were verified using the one-way ANOVA test with Tukey's multiple comparison post-test. The results were considered to be statistically significant when $p < 0.01$.

RESULTS

Antibacterial activity *in vitro*

Eugenol inhibited significantly the planktonic growth of all species of *Streptococcus* tested at concentrations between 250 and 1000 µg/ml, especially *S. mutans* (ATCC 25175), which showed greater sensitivity (Table 1).


Preliminary results for antibiofilm activity in 96-well microplates indicate that eugenol interferes with the biofilm formation process, resulting in considerable inhibition of all the bacteria tested (Figure 1). For the most *Streptococcus* strains, the residual biomass formed was reduced approximately 75 to 90% at minimal tested eugenol concentrations, 15 µg/ml, unless to *S. oralis* (ATCC 10517), which showed dose-response relationship (Figure 1B). However, these results may be related to the specific antimicrobial activity from eugenol, since the concentrations found were lower to MIC values found for the most of microorganisms tested.

A promising result was manifested by *S. mutans*

Table 1. Minimal bacteriostatic and bactericidal concentration against planktonic cell culture of Eugenol against to oral *Streptococcus* strains.

Microorganism	Eugenol ($\mu\text{g/mL}$)	
	MIC	MBC
<i>Streptococcus sp.</i> ATCC 15300	500	1000
<i>Streptococcus salivarius</i> ATCC 7073	1000	1000
<i>Streptococcus oralis</i> ATCC 10517	500	1000
<i>Streptococcus mutans</i> ATCC 25175	250	1000
<i>Streptococcus parasanguinis</i> ATCC 503	500	500
<i>Streptococcus pyogenes</i> ATCC 19615	1000	Nd*

*Nd- Not Determined.

**Figure 1.** Inhibition of biofilm formation of eugenol at different subMIC concentrations against six species of *Streptococcus* reference strains represented as percentage of residual biofilm biomass. *Significantly different ($p < 0.01$). *Streptococcus mutans* ATCC 25175 (A); *S. oralis* ATCC 10517 (B); *S. parasanguinis* ATCC 503 (C); *S. pyogenes* ATCC 19615 (D); *S. salivarius* ATCC 7073 (E); *S. sp.* ATCC 15300 (F). (black bar) Group control; (Gray bar) decreasing concentration of eugenol (15 to 250 $\mu\text{g/mL}$).

(ATCC 25175) indicated at Figure 1A. Beyond being bacterium with clinical relevance in the caries development, it exhibited one of the best responses regarding preliminary antibiofilm activity, performed on polystyrene surface (96-well plate). Even at lower concentrations, 15 $\mu\text{g/mL}$, it decreased around 60% of biofilm biomass compared to untreated group. So, this strain was selected to carry out the experimental biofilm formation on the suture-cotton threads.

Effect of eugenol (E)-suture on initial adhesion of bacteria

In previous antiadhesive tests using E-suture produced in neutral pH, the eugenol groups did not show any differences with the C-suture, control group, after 6 h of initial adhesion. This result is probably due to ionization, since the eugenol in alkaline solution (pH 12) showed better interaction with the cotton-suture (electrically




Figure 2. Antiadhesive effect of eugenol on *S. mutans* ATCC 25175 adhered on the surgical suture. (control) bacteria adhered on C-suture; (2000, 5000 and 8000 µg/ml) bacteria adhered on E-suture at different concentrations ($p < 0.01$).

neutral). After a period of initial adhesion, the E-suture treatment significantly inhibited the adhesion of viable *S. mutans* cells and compared to untreated group (Figure 2). A reduction of more than 50% of colony forming units (CFU) was observed compared to the C-sutures.

Effect of E-suture on biofilm development

The quantification of the *S. mutans* (ATCC 25175) biomass formed on E-suture (2000, 5000 and 8000 µg/ml) was performed by the crystal violet staining method at 0, 12, 24, 36 and 48 h after 6 h of initial adhesion. Significant differences between treatments and the negative control were observed only after 12 h. These differences continued until 48 h, which demonstrates that an early inhibition of the initial adhesion may be prolonged for a time, decreasing the biofilm development and biomass accumulation (Figure 3A). Metabolically active cells of *S. mutans* were monitored by XTT reduction at 24 and 48 h after initial adhesion (6 h) on E-suture at concentrations of 2000, 5000 and 8000 µg/ml. We observed a significant decrease in cellular metabolism in all E-suture groups, while the negative control presented a progressive rise of metabolic activity, proportional to the maturation period (Figure 3B).

At the end of the biofilm development (48 h), all of the E-sutures did not show any visible biofilm layer. In contrast, the control group formed a high amount of biomass with healthy metabolic activity, which was clearly observed through the high optical density values. These results demonstrate that eugenol acts to prevent the initial adhesion of *S. mutans* and, consequently, affects negatively biofilm development.

DISCUSSION

Several researchers have already demonstrated the antimicrobial activity of many essential oils rich in the eugenol are active against a wide range of fungi and Gram-negative and -positive bacteria (Yadav et al., 2013; Marchese et al., 2017). In this case, the analysis was performed against bacteria from the genus *Streptococcus*, which are intrinsically related to biofilm formation and development of diseases in the oral cavity (Tomás et al., 2013). The eugenol activity on bacterial cells is well-studied and the antimicrobial effect is attributed to lipophilic nature, as well as the presence of a free hydroxyl group in the molecule (Nazzaro et al., 2013). Among different hypothesized mechanisms of the eugenol action, the primary approach involves the plasma membrane disruption that increases nonspecific permeability and affects the transport of ions and ATP (Devi et al., 2010; Marchese et al., 2017). Additionally, eugenol is active against certain bacterial enzymes, such as proteases, histidine carboxylases, amylases, and ATPases (Devi et al., 2013). It is highly probable that this versatility of eugenol's mechanism of action reduces the potential of bacteria to develop resistance, which is a serious problem that evolves common antimicrobial agents, such as triclosan (Ciusa et al., 2012).

The effect eugenol may be related to the ability to prevent biofilm organization and to disaggregate micro colonies, as demonstrated by Yadav et al. (2015) against *Streptococcus pneumoniae*. Recently, comparing antibiofilm activity of eugenol and three other eugenol derivatives, researchers suggested that the C-1 hydroxyl unit, the C-2 methoxy unit, and C-4 alkyl or alkane chain on the benzene ring of eugenol play important roles against to Enterohemorrhagic *Escherichia coli* (EHEC) biofilm formation without affecting planktonic cell growth (Kim et al., 2016). Thus, the presence of this antimicrobial compound made the bacteria unable to form biofilms due to antifouling activity of sub-MIC eugenol concentrations (Yadav et al., 2013; Kim et al., 2016).

Sutures impregnated or coated with several antibacterial agents, including plant-derived metabolites, have been extensively explored by many researchers (Reinbold et al., 2017; Sudha et al., 2017). Therefore, the aim of this study was to suggest a safe and inexpensive eugenol-coating for surgical sutures. This molecule may represent a novel alternative for reducing bacterial accumulation and subsequent *S. mutans* biofilm formation on suture threads. Our results showed that, among the bacterial strains, *S. mutans* was one of the most sensitive to eugenol in planktonic and biofilm inhibition assays (Table 1). Thus, this strain was used for subsequent assays involving biofilm formation on cotton-suture threads.

In dental practice, sutures are frequently used in procedures within periodontics, endodontics, implant dentistry, as well as oral and maxillofacial surgery (Kathju




Figure 3. Antibiofilm effect of eugenol-impregnated sutures at different concentrations (2000, 5000 and 8000 µg/mL) on *S. mutans* (ATCC 25175) biofilm development. Cells adhered after 6 hours of initial adhesion were quantified during 48 h of development, with intervals of 12 h to biomass quantification, and 24 h to metabolic rate. Positive control was C-suture. (A) Biomass quantification measured using the dye crystal violet (CV), and (B) metabolic activity by XTT reduction assay. All of the experiments were done in three independent days ($p < 0.01$).

et al., 2009). However, these abiotic structures favor the adhesion and accumulation of pathogenic microorganisms that can initiate an infectious process at the surgical site (Surgical site infection - SSI) and thereby compromise the healing process (Venema et al., 2011). Absorbable and non-absorbable sutures in patients after dental surgery have shown different bacteria adhered on surface. Among these, aerobic and anaerobic bacteria comprised >40 and >25%, respectively, and included pathogenic microorganisms that did not belong in the oral cavity (Otten et al., 2005). Thus, antimicrobial suture coatings have been developed to avoid bacterial adherence and colonization on suture surfaces (Serrano et al., 2015; Gallo et al., 2016; Reinbold et al., 2017).

The effect *in vitro* of eugenol on the cariogenic properties of *S. mutans* was demonstrated previously by Xu et al. (2013). Eugenol inhibited, significantly, the acid production from carbohydrate fermentation, and, as well as, the synthesis of water-insoluble glucans through glucosyltransferases (Gtf) of *S. mutans* inhibition (Li et al., 2012). Similar results were obtained using artificial mouth models with oral bacteria of the genus *Streptococcus*, wherein eugenol was able to eradicate *S. mutans* and *S. sobrinus* biofilms by inhibiting the synthesis of insoluble and soluble glucans (Xiao and Koo, 2010).

The biosynthesis of water-insoluble glucans through glucosyltransferase (Gtf) is an essential Streptococcal mechanism for the adhesion, co-adhesion and bacterial accumulation on the tooth surface, in addition to providing structural integrity for the biofilm matrix (Li et al., 2012). Similarly, there are specific water-insoluble

glucans that promote the adhesive interactions of bacteria with solid surfaces, and inhibition of Gtf activity (particularly GtfC and GtfB) and polysaccharide synthesis is an approach to prevent biofilm-related diseases (Abachi et al., 2016).

Many Gtf inhibitors have been identified in plant-derived compounds, including eugenol, which was recognized for its anti-biofilm capacity using multiple mechanisms, including the direct inhibition of Gtf activity (Xu et al., 2013; Ren et al., 2016). Our results show that eugenol adsorbed to the E-suture surface may work as a Gtf inhibitor, resulting in a decrease of water-insoluble glucans synthesis which, in turn, reduced the number of bonded cells on the E-suture surface (Figure 2), as well as biofilm development (Figure 3). The results of crystal violet and XTT methods showed a minor level of attached cells in the E-suture treatment were able to develop into a biofilm; however, the amount was considerably statistically less than the untreated C-suture group.

Currently, cotton sutures are the most commonly used materials for skin closure, and such material is not commercially available with antimicrobial properties, such as Vicryl® Plus, which is coated by triclosan and considered the "gold standard".

Bioactive compounds, such as eugenol, are a promising alternative to triclosan, which has demonstrated doubtful effectiveness for some surgical interventions (Sewlikar et al., 2015). Furthermore, triclosan has been classified as an "emerging environmental contaminant", that has been directly related to the spreading of antibiotic resistance in clinically important strains (Carey and McNamara, 2015).

Conclusion

Eugenol successfully exhibited modest antiadhesive and antibiofilm properties when used to cover the cotton-suture surface. Although there was no dose-dependent effect, it is noteworthy that the eugenol film adsorbed to the E-suture and promoted a high level of inhibition of cell adhesion and biofilm maturation of *S. mutans* (ATCC 25175). Thus, the present data show that eugenol is an inexpensive antifouling alternative to protect surgical sutures. However, new studies are strongly recommended to increase the knowledge regarding molecules that can control the initial adhesion and formation of the first cell aggregates of *S. mutans*. The continuation of this research may help to identify new compounds for the prevention of infections associated with biomaterials.

CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

ACKNOWLEDGMENTS

This research was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES-Brazil) under grant number 88881.064942/2014 PAJT – Science without Borders Program, coordinated by Prof. Dr. Rodrigo Maranguape. We would also like to show our gratitude to the institutions, University Center INTA and Federal University of Ceara, for supporting us during the course of this research. We are also grateful to “anonymous” reviewers for helped with the english editing by AJE (American Journal Experts).

REFERENCES

- Abachi S, Lee S, Rupasinghe HP (2016). Molecular mechanisms of inhibition of streptococcus species by phytochemicals. *Molecules* 21(215):1-31.
- Al-Jumaili A, Kumar A, Bazaka K, Jacob MV (2018). Plant secondary metabolite-derived polymers: a potential approach to develop antimicrobial films. *Polymers* 10(515):1-24.
- Aranya AK, Pushalkar S, Zhao M, LeGeros RZ, Zhang Y, Saxena D (2017). Antibacterial and bioactive coatings on titanium implant surfaces. *Journal of Biomedical Materials Research Part A* 105(8):2218-2227.
- Bazaka K, Jacob MV, Crawford RJ, Ivanova EP (2011). Plasma-assisted surface modification of organic biopolymers to prevent bacterial attachment. *Acta Biomaterial* 7(5):2015-2028.
- Billings N, Birjiniuk A, Samad TS, Doyle PS, Ribbeck K (2015). Material properties of biofilms – key methods for understanding permeability and mechanics. *Reports on Progress in Physics* 78(3):1-33.
- Busscher HJ, van der Mei HC, Subbiahdoss G, Jutte PC, van den Dungen JJAM, Zaat SAJ, Schultz MJ, Grainger DW (2012). Biomaterial-associated infection: locating the finish line in the race for the surface. *Science Translational Medicine* 4(153):1-10.
- Carey DE, McNamara PJ (2015). The impact of triclosan on the spread of antibiotic resistance in the environment. *Frontiers in Microbiology* 5(780):1-11.
- Chen J, Deng F, Hu Y, Sun J, Yang Y (2015). Antibacterial activity of graphene-modified anode on *Shewanella oneidensis* MR-1 biofilm in microbial fuel cell. *Journal of Power Sources* 290(20):80-86.
- Ciusa ML, Furi L, Knight D, Decorosi F, Fondi M, Raggi C, Coelho JR, Aragones L, Moce L, Visa P, Freitas AT, Baldassarri L, Fani R, Viti C, Orefici G, Martinez JL, Morrissey I, Oggioni MR (2012). A novel resistance mechanism to triclosan that suggests horizontal gene transfer and demonstrates a potential selective pressure for reduced biocide susceptibility in clinical strains of *Staphylococcus aureus*. *International Journal of Antimicrobial Agents* 40(3):210-220.
- Chu CC, Williams DF (1984). Effects of physical configuration and chemical structure of suture materials on bacterial adhesion. A possible link to wound infection. *The American Journal of Surgery* 147(2):197-204.
- Clinical and Laboratory Standards Institute (CLSI) (2012). Methods for antimicrobial susceptibility testing of anaerobic bacterial: Approved Standard. CLSI document M11-A8 Wayne, PA: Clinical and Laboratory Standards Institute.
- Costa Neto ODC, Lobo LA, Iorio NLP, Vasconcelos MFC, Maia LC, Tannure PN, Antonio AG (2015). Oral bacteria adherence to suture threads: an in vitro study. *Oral and Maxillofacial Surgery* 19(3):275-280.
- Devi KP, Nisha SA, Sakthivel R, Pandian SK (2010). Eugenol (an essential oil of clove) acts as an antibacterial agent against *Salmonella typhi* by disrupting the cellular membrane. *Journal of Ethnopharmacology* 130(1):107-115.
- Devi KP, Sakthivel R, Nisha SA, Suganthi N, Pandian SK (2013). Eugenol alters the integrity of cell membrane and acts against the nosocomial pathogen *Proteus mirabilis*. *Archives Pharmacol Research* 36(3):282-292.
- Gallo AL, Paladini F, Romano A, Verri T, Quattrini A, Sannino A, Pollini M (2016). Efficacy of silver coated surgical sutures on bacterial contamination, cellular response and wound healing. *Materials Science and Engineering: C* 69(1):884-893.
- Hoshino S, Yoshida Y, Tanimura S, Yamauchi Y, Noritomi T, Yamashita Y (2013). A study of the efficacy of antibacterial sutures for surgical site infection: a retrospective controlled trial. *International Surgery* 98(2):129-132.
- Kathju S, Nistico L, Hall-Stoodley L, Post JC, Ehrlich GD, Stoodley P (2009). Chronic surgical site infection due to suture-associated polymicrobial biofilm. *Surgical Infections* 10(5):457-461.
- Khalil AA, Rahman U, Khan MR, Sahar A, Mehmood T, Khan M (2017). Essential oil eugenol: sources, extraction techniques and nutraceutical perspectives. *RSC Advances* 52(7):32669-32681.
- Kim YG, Lee JH, Gwon G, Kim SI, Park JG, Lee J (2016). Essential oils and eugenols inhibit biofilm formation and the virulence of *Escherichia coli* O157:H7. *Scientific Reports* 6:36377.
- Li MY, Lai GY, Wang J, Ye DX (2012). The inhibition of eugenol on glucan is essential for the biofilm eradication effect on caries-related biofilm in an artificial mouth model. *Natural Product Research* 26(12):1152-1155.
- Macià MD, Rojo-Molinero E, Oliver A (2014). Antimicrobial susceptibility testing in biofilm-growing bacteria. *Clinical Microbiology and Infection* 20(10):981-990.
- Marchese A, Barbieri R, Coppo E, Orhan IE, Daglia M, Nabavi SF, Izadi M, Abdollahi M, Nabavi SM, Ajami M (2017). Antimicrobial activity of eugenol and essential oils containing eugenol: A mechanistic viewpoint. *Journal Critical Reviews in Microbiology* 43(6):668-689.
- Meghil MM, Rueggeberg F, El-Awady A, Miles B, Tay F, Pashley D, Cutler CW (2015). Novel coating of surgical suture confers antimicrobial activity against *Porphyromonas gingivalis* and *Enterococcus faecalis*. *Journal of Periodontology* 86(6):788-794.
- Nazzaro F, Fratianni F, De Martino L, Coppola R, De Feo V (2013). Effect of essential oils on pathogenic bacteria. *Pharmaceuticals* 6(12):1451-1474.
- Okuda T, Okuda K, Kokubu E, Kawana T, Saito A, Ishihara K (2012). Synergistic effect on biofilm formation between *Fusobacterium nucleatum* and *Capnocytophaga ochracea*. *Anaerobe* 18(1):157-161.
- O'Toole GA (2011). Microtiter dish biofilm formation assay. *Journal of Visualized Experiments* 47:2437.

- Otten JE, Wiedmann-AI-Ahmad M, Jahnke H, Pelz K (2005). Bacterial colonization on different suture materials - A potential risk for intraoral dentoalveolar surgery. *Journal of Biomedical Materials Research Part B: Applied Biomaterials* 74(1):627-635.
- Reinbold J, Uhde AK, Müller I, Weindl T, Geis-Gerstorfer J, Schlensak C, Wendel HP, Krajewski S (2017). Preventing surgical site infections using a natural, biodegradable, antibacterial coating on surgical sutures. *Molecules* 22(9):1570.
- Ren Z, Chen L, Li J, Li Y (2016). Inhibition of *Streptococcus mutans* polysaccharide synthesis by molecules targeting glycosyltransferase activity. *Journal of Oral Microbiology* 8(1):31095.
- Savoia D (2012). Plant-derived antimicrobial compounds: alternatives to antibiotics. *Future Microbiology* 7(8):979-990.
- Selvi F, Cakarar S, Can T, Topcu SIK, Alen Palancioglu A, Keskin B, Bilgic B, Yaltirik M and Keskin C (2016). Effects of different suture materials on tissue healing. *Journal Istanbul University Faculty of Dentistry* 50(1):35-42.
- Serrano C, García-Fernández L, Fernández-Blázquez JP, Barbeck M, Ghanaati S, Unger R, Kirkpatrick J, Arzt E, Funk L, Turón P, del Campo A (2015). Nanostructured medical sutures with antibacterial properties. *Biomaterials* 52:291-300.
- Sewlikar SA, Pillai RS, Mahajan NS, Desai AA (2015). Triclosan coated sutures: an overview of safety and efficacy in reducing risk of surgical site infection. *International Surgery Journal* 2(1):1-7.
- Stewart PS (2015). Antimicrobial tolerance in biofilms. *Microbiology Spectrum* 3(3):1-30.
- Sudha D, Dhurai B, Ponthagam T (2017). Development of herbal drug loaded antimicrobial silk suture. *Indian Journal of Fibre and Textile Research* 42(3):286-290.
- Tomás I, García-Caballero L, López-Alvar E, Suárez-Cunqueiro M, Diz P, Seoane J (2013). *In situ* chlorhexidine substantivity on saliva and plaque-like biofilm: Influence of circadian rhythm. *Journal of Periodontology* 84(11):1662-1672.
- Trentin DS, Silva DB, Frasson AP, Rzhepishevskaya O, Silva MV, Pulcini EL, James G, Soares GV, Tasca T, Ramstedt M, Giordani RB, Lopes NP, Macedo AJ (2015). Natural green coating inhibits adhesion of clinically important bacteria. *Scientific Reports* 5(8287):1-10.
- Venema S, Abbas F, van de Belt-Gritter B, van der Mei HC, Busscher HJ, van Hoogmoed CG (2011). *In vitro* oral biofilm formation on triclosan-coated sutures in the absence and presence of additional antiplaque treatment. *Journal of Oral and Maxillofacial Surgery* 69(4):980-985.
- Wu X, Kubilay NZ, Ren J, Allegranzi B, Bischoff P, Zayed B, Pittet D, Li J (2017). Antimicrobial-coated sutures to decrease surgical site infections: a systematic review and meta-analysis. *European Journal of Clinical Microbiology and Infectious Diseases* 36(1):19-32.
- Xiao J, Koo H (2010). Structural organization and dynamics of exopolysaccharide matrix and microcolonies formation by *Streptococcus mutans* in biofilms. *Journal of Applied Microbiology* 108(6):2103-2113.
- Xu JS, Li Y, Cao X, Cui Y (2013). The effect of eugenol on the cariogenic properties of *Streptococcus mutans* and dental caries development in rats. *Experimental and Therapeutic Medicine* 5(60):1667-1670.
- Yadav MK, Go YY, Chae SW, Song JJ (2015). The small molecule DAM inhibitor, pyrimidinedione, disrupts *Streptococcus pneumoniae* biofilm growth in vitro. *PLoS One* 10(10):e0139238.
- Yadav MK, Park SW, Chae SW, Song JJ, Kim HC (2013). Antimicrobial activities of *Eugenia caryophyllata* extract and its major chemical constituent eugenol against *Streptococcus pneumoniae*. *Acta Pathologica, Microbiologica, et Immunologica Scandinavica* 121(12):1198-1206.

Full Length Research Paper

Utility of molecular diagnostic method compared with conventional methods in detection of etiologic agents of central nervous system infections in Rwanda

Edouard Ntagwabira^{1,2*}, Marianne Wanjiru Mureithi², Jean Baptiste Mazarati¹, Walter Jaoko² and Omu Anzala²

¹Department of Biomedical Services, Rwanda Biomedical Center, Kigali, Rwanda.

²Department of Medical Microbiology, School of Medicine, University of Nairobi, Nairobi, Kenya.

Received 28 November, 2018; Accepted 28 January, 2019

The incidence of meningoencephalitis in developing countries is high and its diagnosis being inadequate as it is mainly based on conventional methods with a limited diagnostic capacity for bacterial, fungal and viral detection. This results in prescription of a cocktail of antibiotics, antifungal, or anti-viral drugs, since the causative agent is often unknown. There is therefore need for timely and appropriate diagnosis to guide treatment. This study aims at evaluating the utility of molecular diagnostic over conventional methods in detection of etiologic agents of central nervous system infections in Rwanda. Using a cross sectional design, 845 hospitalized patients suspected to have meningoencephalitis were enrolled from 8 study sites across the country. Four sterile tubes of Cerebral Spinal Fluid (CSF) specimens were collected from each patient. Two tubes were analyzed on site for bacteriology, fungal, biochemistry and cytology while the other two were transported to the National Reference Laboratory (NRL) for culture and Real-Time Multiplex Polymerase Chain Reaction (PCR) assays. Data entry and analysis was done using Epi Info7, Excel; SPSS and STATA16. In the study, no viruses were detected using the conventional methods while a range of viruses, 152/845 (18%) were detected using real time multiplex PCR. In addition, 185/845 (22%) samples were detected as positive for different types of bacteria using the PCR compared with the 59/845(7%) that were positive using conventional methods. There was however no difference in the detection capacity of fungal agents between the two methods with a detection level of 6% (49). This study has shown increased capacity for detection of bacterial and viral causative agents of Central Nervous System (CNS) infections using RT multiplex PCR compared with conventional methods. This result facilitated the development of a novel algorithm for both conventional and molecular diagnostic methods for CNS infections.

Key words: Meningoencephalitis, RT- Multiplex PCR, conventional methods, causative agents, diagnostic capacity, cerebral spinal fluid.

INTRODUCTION

The etiology of CNS infections varies by age and place. According to previous studies, bacterial meningitidis accounts for approximately 30 to 40% of CNS infections while the remaining 60 to 70% are caused by

cryptococcal, viral, protozoa, brain abscess and other etiologic agents (Mengistu et al., 2013).

In Sub-saharan Africa, *Neisseria meningitidis* infection rates can be as high as 1 in 1000 to 1 in 100 as compared

to about 1 in 100,000 in United States (Richardson et al., 2002). More than 90% of *Neisseria meningitidis* infections in Sub-Saharan Africa are caused by serogroups Y, W135, C, B, and A.

Meningoencephalitis is a serious disease resulting from an acute inflammation of meninges which causes significant morbidity and mortality (Baskin and Hedlund, 2007).

At the initial stage of meningoencephalitis, no reliable clinical indicators are available to differentiate between bacterial, viral, fungal or protozoal infections. As a result, all suspected cases of meningoencephalitis are normally referred for hospitalization. It is very important to identify the causative agents of the meningoencephalitis at an early stage, and determine the appropriate treatment in order to minimize unnecessary antibiotic, antiviral, antifungal and antiparasitic prescriptions (Baskin and Hedlund, 2007).

Bacterial meningitides is mostly caused by *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Neisseria meningitidis*, *Listeria monocytogenes* and group B *Streptococci* (Bartt, 2012). In children, the common causes of meningococcal infection are *Haemophilus influenzae* type b (*Hib*) and *S. pneumoniae* (Taylor et al., 2012).

Viral meningitidis is mostly caused by Enteroviruses and is associated with neurological complications and mortality in 35 to 83%, followed by mumps distant second with 1 to 40% (Minjolle et al., 2002). Other viruses that also cause CNS disease are herpes viruses, toga viruses, bunya viruses, lymphocytic choriomeningitis virus, measles and rubella viruses.

Cytomegalovirus (CMV) infections occur mostly in patients with AIDS causing sub-acute encephalitis. Congenital CMV, which is a much more serious form of infection, has a significant association with morbidity and mortality (Bartt, 2012). In immunocompetent individuals, adenovirus is a rare cause of meningitidis but it remains a key cause of upper respiratory infections in immunocompromised persons (Cho and Mckendall, 2014). Early treatment with acyclovir can significantly reduce morbidity caused by CMV (Bartt, 2012).

In the past, diagnosis of viral meningoencephalitis has been difficult, but it is improving with newer molecular methods (Logan and MacMahon, 2008). The clinical outcome of viral encephalitis is favorable when treatment is done early. Therefore, underlining the importance of early specific diagnosis of meningitis and encephalitis (Baskin and Hedlund, 2007).

Fungi cause severe infections but are much less frequent than bacterial or viral infections. The most common causes of fungal meningoencephalitis are

Cryptococcus neoformans, *Candida albicans* and *Aspergillus* species especially in immunocompromised patients (Baskin and Hedlund, 2007).

Conventional diagnostic methods relying on isolation of bacteria from CSF has previously been shown to be unreliable due to time of culture and prior administration of antibiotics before CSF collection (Ntagwabira et al., 2017). Taken together, there is a need for prompt molecular diagnosis of meningoencephalitis so as to guide early and appropriate treatment and avoid clinical scenarios whereby a patient receives empirically, a cocktail of antibiotics in the absence of causative agent detection.

MATERIALS AND METHODS

The sample collection was conducted between February 2017 and February 2018 on 845 consecutively sampled inpatients from four referrals, and four satellite hospitals with bacteriology laboratories namely King Faisal, Rwanda Military, Butare University Teaching and Kigali University Teaching Referral Hospitals; and four satellites hospitals namely, Gisenyi, Kibungo, Nyagatare and Byumba satellite hospitals.

The study teams composing of medical doctors, nurses and laboratory personnel were recruited from all the sites and centrally trained at the National Reference laboratory on the criteria for patient recruitment, sample collection, storage and transportation.

All consenting and assenting inpatients and coma patients' proxies of all ages with clinical signs and symptoms of meningoencephalitis were recruited into the study.

Patients with International Normalized Ratio (INR) of less than 1.5 and those with a platelet count of less than 50,000 were excluded. Similarly, those with intracranial mass and partial/complete spinal block or acute spinal trauma were also excluded.

The physicians in the study sites were responsible for initial clinical diagnosis and selection of meningoencephalitis patients to be enrolled in the study based on case definition and the most frequent common symptoms were not limited to fever, headache, cranial nerve abnormalities and chills, confusion, irritability and neck stiffness (Table 2). Each patient's details were entered into case report form detailing their medical history and the socio-demographic information.

CSF was collected into four individual sterile screw cup tubes with a minimum of 1 ml per tube using standard CSF collection techniques and labelled with the study unique identification number. The CSF from one tube was used for gram stain, Indian ink stain for cryptococcal antigen (Crag) detection and conventional culture at site. Another tube was used for the biochemistry and cytology analysis within one hour. CSF sample of 0.5-1 ml from one of the remaining two tubes was inoculated into Trans-Isolate (TI) culture medium while the other one was stored at - 20°C waiting for transportation to NRL for pathogen detection using culture and RT-multiplex PCR, respectively. During inoculation of the CSF to the media, contamination was avoided by using sterile forceps to remove the aluminum foil covering the medium and disinfecting the stopper with 70% alcohol and allowed to dry. Sterile syringes and

*Corresponding author. E-mail: edouard.ntagwabira@gmail.com.

needles were used during the inoculation.

If transportation for T-I culture medium to NRL was delayed to the next day or longer, averted needle (sterile cotton plugged hypodermic needle) was inserted through the rubber stopper of the T-I medium bottle, which ensured growth and survival of the bacteria.

CSF specimens were handled as potentially infectious. Biosafety guidelines were adhered by using biosafety cabinets during manipulation of the specimens according to the World Health Organization (WHO) and National Reference Laboratory Guidelines.

Sample processing at NRL using conventional method

Each sample has been transported with its consent or assent form and case report form within 4 h after sample collection.

Upon arrival at NRL, the sample in T-I bottle was aseptically inoculated on sheep blood agar, chocolate agar and MacConkey agar. The remaining sample was incubated at 35-37°C in a ~5% CO₂ atmosphere then observed daily for turbidity in the liquid phase for up to 7 days to enhance the growth if the first subculture did not show any growth. The venting needle was inserted in the T-I bottle (sterile cotton-plugged hypodermic needle) through the rubber stopper of the T-I bottle without touching the broth, in order to encourage growth and survival of bacteria.

When T-I became turbid, the sample was cultured on blood agar and chocolate agar incubated at 35-37°C in a ~5% CO₂ atmosphere for 24 h, culture was also done on MacConkey agar and 35-37°C for 18 to 24 h. The T-I at this time was discarded. If no turbidity was observed after 7 days, sample was systematic inoculated on blood agar, chocolate agar and Mac Conkey agar, at this point the T-I was discarded and the final culture was recorded and reported to attending physician.

On sheep blood agar and chocolate agar if there was no growth observed in 24 h, the plates were re-incubated for 48 h before reporting negative culture. The culture growth, identification of colonies was done using Gram staining of young colonies, followed by biochemical testing (API 20E, API NH, catalase, coagulase, oxidase, CAMP test) and serotyping. After bacterial identification antimicrobial susceptibility testing was conducted to all isolated bacteria using recommended antibiotic discs on Mueller-Hinton agar, Kirby-Bauer method and Clinical and Laboratory Standards Institute (CLSI) catalogue for result interpretation.

A small quantity of CSF sample for RT Multiplex PCR was aseptically inoculated on Yeast Extract Peptone Dextrose (YPD) medium and incubated at 35- 37°C; the growth was checked after 48 h. If no growth, the plate was re-incubated and checked daily for up to 7 days. The remaining sample was tightly closed and stored at -20°C for RT multiplex PCR. The colonies growing on YPD were identified using Indian ink and Cryptococci antigen latex agglutination.

The results were recorded on a worksheet, then case report form and entered into Laboratory Information System and Epi-Info database. All positive results were communicated to attending physician immediately by phone call and all printed results were sent by sample transportation car going to each hospital once weekly or given to research site laboratory technologist under research team bringing samples at NRL.

Quality assurance on conventional method

Quality assurance system and continuous monitoring was built to ensure that all procedures were performed proficiently, adequately and correctly.

Quality, accuracy and reliability of the study results on conventional method was validated and verified based on the NRL-

External Quality Control (EQC) policy. The known positive samples were selected from the NRL archived strains. The available strains for positive control were *N. meningitidis*, *S. pneumoniae*, and *H. influenzae* B, from the NHLS, South Africa and *C. neoformans* from NRL archive as well as ATCC bacterial species (*S. pneumoniae*, *E. coli* and *H. influenzae* B). All samples were processed according to the Standard Operating Procedures.

Samples analysis using RT Multiplex PCR

RT multiplex PCR assay validation

Quality control

Known positive control strains used during culturing above were also used as the positive control for the bacteria detection and specificity of the PCR assays. The strains had been sub-cultured from the skim milk and thus DNA extraction had to be performed.

The reliability of the study was validated and verified based on the NRL-EQC policy. The known positive samples were selected from the NRL archived strains. The available strains for positive control were *N. meningitidis*, *S. pneumoniae*, and *H. influenzae* B, from the NHLS, South Africa and *C. neoformans* from NRL archive as well as ATCC bacterial species (*N. meningitis*, *S. pneumoniae*, *E. coli* and *H. influenzae* B).

Nucleic acid extraction

Nucleic acid was extracted from the known positive controls: *N. meningitidis*, *S. pneumoniae*, *H. influenzae* B, *C. neoformans* and *E. coli* using an automated nucleic acid extraction platform (QIASymphony SP-QIAGEN, Germany). The QIASymphony DSP virus /pathogen mini kit was used according to manufacturer's instruction with a starting volume of 250 µl and an elution volume of 60 µl. The QIASymphony SP uses the magnetic bead technology, where the viral/pathogen cells are first lysed to release the nucleic acid. The released nucleic acid binds to the magnetic particles allowing separation of the nucleic acid.

The nucleic acid was then purified by washing in the series of wash buffer on rod covers before finally being released in the elution buffer. Sterile nuclease free water was used as a negative control of extraction.

The extracted nucleic acid was collected in elution racks, labelled and quantified using QiAxpert nucleic acid quantifier system (QIAGEN, Germany) to establish the quality and quantity of the eluates. The quality of extracted nucleic acid was validated on wavelengths of 230/260 and 260/280 ratios to check for sample purity. The eluted nucleic acid was used directly in Real time-PCR and the excess stored at -80°C for long storage or 4 to 8°C for short storage.

Master mix preparation

Pre-optimized Commercial RT-Multiplex PCR kits for *in-vitro* diagnostics were used. The kits comprising PCR buffer, primer and probe mix (PPmix) and Taq polymerase enzyme were provided in three separate tubes and required constitution of the master mix before adding the templates. Both automated and manual master mix preparations were evaluated for their efficiency in processes and also on optimal reagent usage. QIAgility (QIAGEN, Germany) liquid handler was used for the master mix. The system was programmed to pipette 12.5 µl of PCR buffer, 1.5 µl of PPmix, 1.5 µl of the enzyme and 2 µl of internal control into a 1.5 ml tube and later aliquoted 15 µl into individual 0.1 ml PCR ml tubes that were compatible with the thermalcycler (Rotor Gene Q, QIAGEN-

Table 1. Detection guide for the targets in the kits.

Kit Name	Tube	Green dye (Wavelength-520 nm)	Yellow dye (Wavelength-550 nm)	Orange dye (Wavelength-610 nm)	Red dye (Wavelength-670 nm)
FTD Neuro9	1	<i>EBV</i>	<i>CMV</i>	IC	AVE(NC)
	2	<i>HSV1</i>	<i>HSV2</i>	IC	VZV
	3	<i>EV</i>	PV	IC	-
	4	<i>HHV6</i>	<i>B19</i>	<i>HHV7</i>	-
FTD Bacterial Meningitis kit	1	<i>H. influenzae</i>	<i>N. meningitidis</i>	IC	<i>S. Pneumoniae</i>
FTD Neonatal meningitidis kit	1	Group B <i>Streptococci</i>	IC	<i>E.coli</i>	<i>Listeria monocytogenes</i>
	2				
<i>Cryptococcus neoformans</i> Real-TM kit	1	IC	<i>Cryptococcus</i>		

Germany). 10 µl of the extracted sample nucleic acid was added to the master mix into each tube including the extracted negative control sample. Positive and negative controls from the manufacturer were included in each run. In total, four RT-Multiplex PCR kits were used namely: FTD bacterial meningitis (*N. Meningitidis*, *S. pneumoniae* and *H. influenzae*)-Fast Track Diagnostics, Luxembourg, FTD Neonatal meningitis kit (*S. agalactiae*/Group B *Streptococcus*, *Listeria monocytogenes* and *E. coli*)-Fast Track Diagnostics, Luxembourg, *C. neoformans* Real-TM kit (*C. neoformans*)-Sacace Biotechnologies, Italy and FTD Neuro9 kit (*human Adenovirus-ADV*, *human Cytomegalovirus-CMV*, *Epstein-Barr virus-EBV*, *Herpes simplex virus-HSV, 1 and 2*, *Varicella zoster virus -VZV*, *Enterovirus*, *human parechovirus -HPV*, *human herpesvirus 6 and 7*, and *human parvovirus B19*)-Fast Track Diagnostics, Luxembourg. The PCR setup for the *Cryptococcus neoformans* entailed 10 µl of PCR mix -1, 1.5 µl of PCR mix-2, 0.5 µl of DNA Polymerase, 2 µl of internal control and sterile water into each PCR reaction tube followed by 10 µl of the extracted nucleic acid. Specificity of the assays was tested by amplifying known strains in the kits without their targets. The tubes were sealed, labelled and transferred to the real time thermalcycler (Rotor Gene Q -, Germany) for amplification.

Amplification

The commercial pre-optimized RT Multiplex PCR kits contain all the necessary reagents for amplification. Each primer and probe mix has been specifically designed to target specific pathogen targets and validated for specificity but checking the possibility to amplify related pathogens. In the case of viruses, the viral RNA is transcribed into cDNA using a specific primer mediated reverse transcription step followed immediately in the same tube by polymerase chain reaction. The DNA is amplified simultaneously in the same tube by polymerase chain reaction. In situations of multiplex PCR, the reaction will have a cocktail of primers and probes targeting multiple pathogens. The presence of specific pathogen sequences in the reaction is detected by an increase in fluorescence observed from the relevant dual-labeled probe, and reported as a cycle threshold value (Ct) by the Real-time thermocycler. The assays use murine *Cytomegalovirus* (mCMV) and Brome mosaic virus (BMV) as the internal control. The internal

control is introduced into each PCR reaction tube during the PCR setup to check for PCR efficiency.

The kits use similar amplification programme involving an initial enzyme activation step at 95°C for 15 min and 5 cycles comprising of denaturation at 95°C for 5 s, annealing step at 60°C for 20 s and extension step at 72°C for 15 s without fluorescence detection.

This was followed by 40 cycles comprising denaturation at 95°C for 5 s, annealing step at 60°C for 15 s and extension step at 72°C for 15 s with fluorescence detection on four detection channels of the thermocycler as indicated in Table 2.

Similarly, the pre-optimized commercial Real-Time PCR kits was used for detection of *Cryptococcus neoformans* and entailed an initial enzyme activation step at 95°C for 15' min and 5 cycles comprising denaturation at 95°C for 5 seconds, annealing step at 60°C for 20 s and extension step at 72°C for 15 s without fluorescence detection, followed by 40 cycles comprising denaturation at 95°C for 5 s, annealing step at 60°C for 20 s and extension step at 72°C for 15 s with fluorescence detection on green and yellow at the annealing step at 60°C

Interpretation of the PCR assays

Specific probes were detected on four different channels on Rotor Gene Q which were matched up with specific pathogens as shown in Table 1. The detection involves analyzing the PCR assay upon completion of the run to check the validity of the assay by confirming absence of any contamination and establishing PCR amplification efficiency. The process entails using the Rotor Gene Q software to first check for contamination by analyzing the negative controls. The threshold is set at a point where the negative control is below the threshold and the Ct value for the positive and internal controls is below 33 while the amplification exhibits positive (exponential) trace as guided by the manufacturer instructions commercial kits. Any specimen displaying an exponential trace with a Ct value below 33 is considered positive. A detection guide outlined in Table 1 was provided by the manufacturer for establishing the pathogens detected in the positive samples. Appearance of any curve in the negative control was considered as potential contamination, and therefore the results obtained were not interpretable. The whole run including extraction had to be repeated. The run was also repeated where the positive and

Table 2. Frequency of meningoencephalitis symptoms by age group.

Signs and symptoms	0 – 4 years	5 – 14 years	15 – 24 years	25 – 34 years	35 – 44 years	45 – 54 years	>= 55 yrs	Total
Chills	0	2	2	1	5	1	2	13
Coma	5	7	15	12	8	7	11	65
Confusion	19	20	40	67	56	30	32	264
Convulsions	75	31	28	21	15	10	10	190
Cranial nerve abnormalities	1	0	1	2	0	0	0	4
Fever	124	65	130	136	95	57	56	663
Headache	32	49	151	160	122	69	75	658
Lethargy	28	18	21	19	15	7	14	122
Neck stiffness	19	20	74	58	53	32	31	287
Neurological deficit	1	3	4	6	3	2	6	25
Irritability	43	28	62	69	57	37	37	333
Photophobia	21	19	52	66	52	27	31	268
Kernig sign Brunziski	3	2	10	7	8	1	5	36
Nausea	43	35	70	64	68	28	33	341
Vomiting	43	34	57	43	46	21	17	261

internal controls did show amplification curves.

The validation of the RT multiplex PCR Assays was considered successful upon detection of the known NRL strains used as positive controls of nucleic acid purification. The assays also amplified the positive and internal controls provided in the kits while both the negative control of purification and the one provided in the kit did not amplify.

Table 1 shows the detection guide for the targets in the four RT PCR kits used for analysis of 845 samples from patient suspect to have CNS infections.

Upon validation of the assays, nucleic acid from the patients' samples were extracted, quantified and amplified as per the above validated protocols with reference to manufacturer's instructions.

Ethical consideration

This study was reviewed and approved by both Rwanda National Ethical Committee and Kenyatta National Hospital/University of Nairobi Ethics and Research Committee prior to its commencement. The approval numbers are No 572/RNEC/2041, KNH/UON ERC-P561/09/2014 respectively. Written informed consent was

obtained from all patients or proxies of comatose patients aged 18 years and above. In addition, assent was obtained from parents/guardians of children aged below 18 years by the signing of assent forms. The study was explained to the study participants by the nurses at the sites to ensure that they understood the significance, design and objectives and any risks that may be involved. Privacy and confidentiality of the patients was upheld at all stages of the study. All study subjects were informed that they were free to withdraw their participation from the study at any stage without any loss of benefits or penalty. Personal identifiers were removed from all the data and replaced with unique numbers.

RESULTS

A total of 845 CSF samples obtained from patients suspected to be having meningoencephalitis were analyzed in this study using conventional and molecular diagnostic methods. The total number of female patients was 434 (51.4%) of the study population while male

patients were 411(48.6%) of the study population.

Characteristics of study population

Figure 1 shows the demographic representation of the age groups in the study. About 65% of the study population was below 35 years of age. The most frequently affected population was the age group of 25 to 34 years' old which constituted 21% of the patients seen followed by group aged 15 to 20 years which constituted 20% of the patients. The least frequently affected age group was that aged 5 to 14 years old constituting 9% of the patient population.

Clinical characteristics of study population

Table 2 shows the frequency of signs and




Figure 1. Demographic representation of study population by age group (n=845).

Table 3. The pathogen isolates compare with CSF protein concentration.

Pathogen	< 45 mg/dl	≥ 45 mg/dl	Total
<i>Streptococcus agalactiae</i>	2	3	5
<i>Cryptococcus neoformans</i>	3	46	49
<i>Escherichia coli</i>	19	11	30
<i>Klebsiella pneumoniae</i>	1	3	4
<i>Staphylococcus coagulase negative</i>	0	9	9
<i>Staphylococcus aureus</i>	5	5	10
<i>Streptococcus pneumoniae</i>	4	1	5
Total	34	78	112

Table 4. The pathogen isolated compared with glucose concentration in CSF.

Pathogen	≤40 mg/dl	>40 mg/dl	Total
<i>Streptococcus agalactiae</i>	3	2	5
<i>Cryptococcus neoformans</i>	36	13	49
<i>Escherichia coli</i>	9	21	30
<i>Klebsiella pneumoniae</i>	3	1	4
<i>Staphylococcus coagulase negative</i>	6	3	9
<i>Staphylococcus aureus</i>	4	6	10
<i>Streptococcus pneumoniae</i>	2	3	5
Total	63	49	112

symptoms in patients suspected to have meningoencephalitis. The most frequently observed sign was fever, seen in 663 (75.8%) of the patients while headache was the most frequently reported symptom by 658 (75.2%) of the patients. Only 4(0.5%) and 13(1.5%) had cranial nerve abnormalities or chills, respectively.

Table 3 indicates that according to protein concentration in CSF samples, there are two groups: one with protein below 45 mg/dl and another one with protein

equal to 45 mg/dl and above. The normal protein concentration in CSF is below 45 mg/dl.

Isolated *Staphylococcus coagulase negative* 9/ 9 (100%) showed significantly higher CSF protein concentration than other isolated microorganisms, followed by *C. neoformans* 46 / 49 having significantly higher CSF protein concentration (93.9%).

Table 4 shows the normal glucose concentration in CSF is between 45–80 mg/dl. The patients with bacterial

Table 5. Frequency of pathogen isolates by age group using culture at NRL.

Pathogen Isolated	Age group							Total
	0 - 4	5 - 14	15 - 24	25 - 34	35 - 44	35 - 54	>55	
<i>Streptococcus agalactiae</i>	2	1	0	0	2	0	0	5
<i>Cryptococcus. neoformans</i>	1	3	7	6	10	12	10	49
<i>Escherichia coli</i>	23	4	1	0	1	1	0	30
<i>Klebsiella pneumoniae</i>	1	0	0	1	0	0	2	4
<i>Staphylococcus coagulase negative</i>	0	0	5	3	0	1	0	9
<i>Staphylococcus aureus</i>	2	1	0	3	1	2	1	10
<i>Streptococcus. pneumoniae</i>	0	1	0	0	0	0	4	5
Total	29	10	13	13	14	16	17	112

Table 6. Distribution of isolated pathogen by gender.

Pathogen isolates	Gender		
	F	M	Total
<i>Cryptococcus neoformans</i>	23	26	49
<i>Escherichia coli</i>	17	13	30
<i>Klebsiella pneumoniae</i>	3	1	4
<i>Staphylococcus coagulase negative</i>	4	5	9
<i>Staphylococcus aureus</i>	4	6	10
<i>Streptococcus agalactiae</i>	3	2	5
<i>Streptococcus pneumoniae</i>	3	2	5
Total	57	55	112

and fungal meningitis have decreased CSF glucose levels. *C. neoformans* was mostly isolated from samples with lower glucose concentration 36 / 49 (73.4%) followed by *Staphylococcus coagulase negative* 6/9 (66.6 %) that showed significantly lower levels of glucose concentration than other isolated microorganisms

Outcome of culture at NRL

The results from culture at NRL showed that out of 845 cultured samples, only 63(7%) samples were positive to different types of bacteria while 49(6%) were positive to *C. neoformans* as indicated in Table 5. In this study there was no virus culture facility, therefore no viruses were detected using conventional method.

Table 5 shows positivity rates for the 845 CSF samples cultured at NRL, whereby 63/845(7%) were positive with bacteria. The most isolated bacteria were *E. coli* 30/63 (48%), which was more isolated from children between 0 to 4 years, followed by *S. aureus* 10 (16%), *S. coagulase negative* 9 (14%), *S. agalactiae* 5(8%), *S. pneumoniae* 5 (8%); and *K. pneumoniae*, 4(6%). Similarly, 49 samples out of 845 (6%) were positive for *C. neoformans*.

Table 6 shows the pathogens isolated from culture compared in relationship to gender. There is no significant difference in the isolated pathogens from men

and women, since isolates from men were 55/411 (13%) and that from women were 57/434 (13%).

Outcome of RT-Multiplex PCR at NRL

Using the developed and validated RT-Multiplex PCR algorithm, 845 CSF samples were collected and analyzed. 152 (18%) were positive for the detected viruses below: *Adenovirus* 38/ 845 (5%), *Epstein-Barr virus* 22 / 845 (3%), *Cytomegalovirus* 7/845 (1%), *Human Herpes virus* (6) 17/845 (2%), *Human Herpes virus* (7) 3/ 845(0%), *Herpes simplex virus* (1) 6 /845 (1%) and *Herpes simplex virus* (2) 3 / 845 (0%), *Enterovirus* 52 /845 (6%) and *Human Parechovirus* 4 /845 (0%). Among the total viral isolates obtained from CSF, the most commonly detected virus was *Enterovirus* 52 /152 (34%), *Adenovirus* 38/152 (25%), *Epstein-Barr virus* 22/152 (15%), *Human Herpes virus* (6) 17/152 (11 %), *Cytomegalovirus* 7/ 152 (5%), *Herpes simplex virus* (1%) 6 /152 (4 %), *Human Parechovirus* 4 out of 152 (3%), *Herpes simplex virus* (2) 3 out of 152 (2%), *Human Herpes virus* (7%) 3/ 152 (2%). Only 216 samples were analyzed for detection of *Varicella-Zoster virus* and *Parvovirus* B19 due to unavailability of reagents. The prevalence of these viruses based on the samples analyzed were as follows: *Varicella-Zoster* 1/216 (1%)

Table 7. Frequency of virus detected using RT multiplex PCR.

Pathogen	Frequency	Positivity rate (%)	Prevalence (%)
<i>Epstein-Barr virus</i>	22	14	3
<i>Cytomegalovirus</i>	7	5	1
<i>Adenovirus</i>	38	25	4
<i>Herpes simplex virus 1</i>	6	4	1
<i>Herpes simplex virus 2</i>	3	2	0
<i>Human Herpes virus 6</i>	17	11	2
<i>Human Herpes virus 7</i>	3	2	0
<i>Enterovirus</i>	52	34	6
<i>Human Parechovirus</i>	4	3	0
Total positive	152		18
Total sample	845		




Figure 2. Representation of Human *adenoviruses* (Ct values).

and *Parvovirus* B19 0/219 (0%) (Table 7).

Figure 2 represents detected virus “*human adenovirus*”. The Ct value of the positive control is 25. The strongest Ct value was 22 seen in sample 2, which is stronger than positive control, followed by sample 145 and 195 both with Ct values of 24. The highest Ct value was 33 with lower positivity. The negative control did not show any Ct value.

Figure 3 represents the *C. neoformans* detected. The positive control Ct value was 21, strongest positive sample has Ct value of 33 which is sample 359 and 369. The lower positive has Ct value of 34 in which 18 samples were overlapping at the same Ct value. Negative control does not show any Ct value.

Table 8 shows the use of RT Multiplex PCR; 845

collected CSF samples were analyzed for bacterial meningitis detection, 88 (10%) samples were positive on the following microorganisms: The most detected was *S. pneumoniae* with 45/88 (51%) followed by *Hemophilus influenzae* 25/ 88(28%) and *Neisseria meningitidis* with 18/ 88 (21%).

Figure 4 represents detected bacteria “the *Streptococcus pneumoniae*”. The positive control Ct value was 24.8; the strongest positive sample has Ct value of 23 which is sample 57. The third positive was known as *Streptococcus pneumoniae* sample one with Ct value of 26.6. The lower positive has Ct value of 31.8 which was known as *Streptococcus pneumoniae* sample two. The control negative does not show any Ct value.

Table 9 shows the use of a neonatal kit, 138 CSF




Figure 3. Representative of *Cryptococcus neoformans* (Ct values).

Table 8. Frequency of bacteria pathogens detected using molecular method.

Pathogen	Frequency	Percentage
<i>Hemophilus influenza</i>	25	3
<i>Neisseria meningitidis</i>	18	2
<i>Streptococcus pneumoniae</i>	45	5
Total positive	88	
Total sample	845	10





Figure 4. Representation of *Streptococcus pneumoniae* detected (Ct values).

Table 9. Frequency of bacteria pathogens detected from neonatal CSF.

Pathogen	Frequency	Prevalence
<i>Listeria monocytogenes</i>	2	1
<i>Escherichia coli</i>	15	11
Total positive	17	12
Total sample	138	

**Figure 5.** Representation of *E. coli* detected (Ct values).

samples were collected and analyzed using molecular methods. 17/138 (12%) samples were positive on following microorganisms. The most detected organism was *Escherichia coli* 15/17 (88%) positive bacteria followed by *Listeria monocytogenes* 2/17 (12%). No Group B *Streptococcus* was isolated.

Figure 5 represents the *E. coli* detected. The strongest Ct value was 7.9. The positive control has Ct value of 26.3. The known sample has Ct value of 26.4. The second strongest Ct value was 10.6 which was sample 559. The third Ct value was 11.6 which was sample 527. The fourth Ct value was 11.9 which was sample 513. The fifth Ct value was 12.4 which was sample 322. The sixth Ct value was 14.8 which was sample 452. The seventh Ct value was 26.4 which was sample 693. The lowest Ct value was 27.5 which was sample 426. The negative control does not show any Ct value.

Figure 6 represents internal control results whereby all Ct values were close together which indicates that the quality of results is quite accurate. This has been used in all samples including negative and positive controls. In some runs, the known sample from accredited external quality control laboratories was included in the runs to ensure the quality of results.

DISCUSSION

The aim of this study is to evaluate the utility of molecular diagnostic compared with conventional diagnostic methods in detection of etiologic agents of central nervous system infections in Rwanda.

The study was encouraged by data collected from hospitalized patients in four referral hospitals for a period of 4 years from 2009 to 2012, which showed the diagnostic capacity of 9% positive and 91% negative on detection of etiologic agents of central nervous system infections.

The above mentioned results were inadequate for doctors to treat patients with appropriate drugs since some bacteria, fungi and all viruses were not detected using conventional methods. This result will help in early and prompt treatment using appropriate drugs based on isolated micro organisms by avoiding the prescription of a cocktail of antibiotics, antifungal, or anti-viral drugs.

The developed novel algorithm for molecular diagnostic techniques has been established at National Reference Laboratory, well equipped with high technology equipment and well trained staff. The developed algorithm will help Ministry of Health in Rwanda to come




Figure 6. Representation of Internal control (Ct values).

up with policy for quick appropriate diagnosis and treatment of meningoencephalitis. This developed novel algorithm will facilitate Ministry of health to plan for decentralization of molecular diagnostic methods within the laboratory network for better applicability and use, which will greatly assist in patient care, treatment and management at all referral laboratories in Rwanda.

The molecular diagnostic techniques improved diagnostic capacities by detecting 152 viral infections using Real-time Multiplex PCR. This represents 18% detection capacities of viral infections and is in agreement with similar study by (Koskiniemi et al., 2001) which reported molecular methods as being specific, highly sensitive and rapid in detection of viral CNS infections.

This study shows that the diagnostic capacity of etiological agents of CNS infection improved from baseline of 9% diagnostic capacities using routine conventional methods (Ntagwabira et al., 2017), to 40% diagnostic capacities using developed novel algorithm. In this study, the molecular method detected viruses as the most common cause of meningoencephalitis. Enterovirus had the highest viral positivity rate of 34%, followed by Adenovirus 25%, Epstein- Barr virus 15%, Human Herpes virus (6) 11%, and Cytomegalovirus 5%. The lowest positivity rate was Varicella-Zoster 1%. Moreover, based on our findings, the molecular diagnostic method improved diagnostic capacity and therapeutic management of CNS infections by detecting multiple viral infections potentially responsible for meningoencephalitis, as reported similarly by (Quereda et al., 2000).

The detection capacity of bacterial infections improved

from 7% using conventional to 22% using molecular diagnostic methods. The usefulness of PCR diagnostic method is supported by previous studies (Issa et al., 2003), which advised the use of PCR diagnostic method in the detection of CNS infection agents. However, the detection capacity of fungal in conventional and molecular methods was the same at 6%.

CONCLUSION AND RECOMMENDATION

This study has shown increased capacity for detection of bacterial and viral causative agents of CNS infections using RT multiplex PCR compared with conventional methods and is recommended for use of molecular diagnostic techniques in diagnosis of CNS infections for better treatment and management of meningoencephalitis suspected patients.

CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

ACKNOWLEDGEMENTS

The authors acknowledge the World Bank through EAPHLNP for funding the research and also appreciate the administrative support provided by the University of Nairobi and Rwanda biomedical centre through SPIU/BIOS/NRL.

REFERENCES

- Bartt R (2012). Acute Bacterial and Viral Meningitis', *CONTINUUM: Lifelong Learning in Neurology* 18(6):1255-1270.
- Baskin HJ, Hedlund G (2007). Neuroimaging of herpesvirus infections in children. *Pediatric Radiology* 37(10):949-963.
- Cho TA, Mckendall RR (2014). Clinical approach to the syndromes of viral encephalitis, myelitis, and meningitis'. *Handbook of Clinical Neurology*. Elsevier 123:89-121.
- Issa M, Mölling P, Bäckman A, Unemo M, Sulaiman N, Olcén P (2003). PCR of cerebrospinal fluid for diagnosis of bacterial meningitis during meningococcal epidemics; an example from Sudan. *Scandinavian journal of infectious diseases* 35(10):719-723.
- Koskiniemi M, Rantalaiho T, Piiparinen H, von Bonsdorff CH, Färkkilä M, Järvinen A, Kinnunen E, Koskiniemi S, Mannonen L, Muttilainen M, Linnavuori K (2001). Infections of the central nervous system of suspected viral origin: a collaborative study from Finland. *Journal of Neurovirology* 7(5):400-408.
- Logan SAE, MacMahon E (2008). Viral meningitis. *British Medical Journal* 336(7634):36-40.
- Mengistu A, Gaeseb J, Uaaka G, Ndjavera C, Kambyambya K, Indongo L, Kalemeera F, Ntege C, Mabirizi D, Joshi MP, Sagwa E (2013). Antimicrobial sensitivity patterns of cerebrospinal fluid (CSF) isolates in Namibia: implications for empirical antibiotic treatment of meningitis. *Journal of Pharmaceutical Policy and Practice* 6(1):4.
- Minjolle S, Arvieux C, Gautier AL, Jusselin I, Thomas R, Michelet C, Colimon R (2002). Detection of herpesvirus genomes by polymerase chain reaction in cerebrospinal fluid and clinical findings. *Journal of Clinical Virology* 25:59-70.
- Ntagwabira E, Mureithi MW, Muvunyi CM, Masaisa F, Nkeshimana M, Mukagatare I, Thuo D, Jaoko W, Mazarati JB, Anzala O (2017). Challenges in diagnosis of central nervous system infections using conventional method: Need for better approach in Rwanda. *African Journal of Microbiology Research* 11(35):1379-1385.
- Quereda C, Corral I, Laguna F, Valencia ME, Tenorio A, Echeverria JE, Navas E, Martín-Dávila P, Moreno A, Moreno V, Gonzalez-Lahoz JM (2000). Diagnostic utility of a multiplex herpesvirus PCR assay performed with cerebrospinal fluid from human immunodeficiency virus-infected patients with neurological disorders. *Journal of Clinical Microbiology* 38(8):3061-3067.
- Richardson AR, Yu Z, Popovic T, Stojiljkovic I (2002). Mutator clones of *Neisseria meningitidis* in epidemic serogroup A disease. *Proceedings of the National Academy of Sciences of the United States of America* 99(9):6103-6107.
- Taylor WR, Nguyen K, Nguyen D, Nguyen H, Horby P, Nguyen HL, Lien T, Tran G, Tran N, Nguyen HM, Nguyen T (2012). The spectrum of central nervous system infections in an adult referral hospital in Hanoi, Vietnam', *PLoS ONE* 7(8):e42099.

Related Journals:

